Upon entering the study, you will be randomly assigned to one of two treatment groups. This process is called randomization and ensures that the assignment is done by chance, similar to flipping a coin.

The first group will receive MK-1084 (a tablet taken by mouth) in combination with pembrolizumab (a medication given as an injection under the skin).

The second group will receive pembrolizumab (injection under the skin) in combination with chemotherapy medications, which include pemetrexed and either carboplatin or cisplatin (both given through a vein).

If you are assigned to the first group, you will take MK-1084 tablets by mouth. You will also receive pembrolizumab as an injection under the skin at scheduled intervals.

If you are assigned to the second group, you will receive pembrolizumab as an injection under the skin. Additionally, you will receive chemotherapy through an infusion into a vein. The chemotherapy consists of pemetrexed combined with either carboplatin or cisplatin.

The specific dosage, frequency, and duration of each medication will be determined according to the study protocol and your individual medical situation.

Throughout the study, you will attend regular visits at the study site for monitoring and assessments.

During these visits, the study team will check your overall health, monitor for any side effects, and assess how the treatment is working.

These visits may include physical examinations, blood tests, imaging scans, and other procedures as required by the study protocol.

At certain points during the study, you will be asked to complete questionnaires about your quality of life and symptoms.

These questionnaires will ask about your overall health status, daily functioning, and specific symptoms such as shortness of breath (dyspnea), cough, and chest pain.

The information collected will help evaluate how the treatment affects your daily life and well-being.

The study team will regularly assess whether your cancer is responding to treatment, staying stable, or progressing.

This assessment is done using imaging scans and follows standardized criteria called RECIST 1.1, which measures changes in tumor size.

The primary goal is to measure progression-free survival, which is the length of time during and after treatment that you live without the cancer getting worse.

Throughout the study, any side effects or adverse events you experience will be carefully recorded and monitored.

You should report any new symptoms or changes in your health to the study team promptly.

If serious side effects occur, the study team may adjust your treatment or, if necessary, discontinue your participation in the study.

You will continue receiving the assigned treatment as long as it is beneficial and you do not experience unacceptable side effects.

The treatment may continue until your cancer progresses, side effects become too severe, or you decide to withdraw from the study.

The study team will regularly evaluate whether continuing treatment is appropriate for you.

After completing the treatment phase, you will enter a follow-up period where the study team will continue to monitor your health status.

During this period, information about your overall survival and long-term outcomes will be collected.

The study is expected to continue until approximately August 2032, though your individual participation duration may vary.